DOI QR코드

DOI QR Code

Bioequivalence of Famcivir Tablet to FamvirTM Tablet 250 mg (Famciclovir 250 mg)

팜비어 정 250밀리그람(팜시클로버 250 mg)에 대한 팜시버 정의 생물학적동등성

  • Kang, Hyun-Ah (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Cho, Hea-Young (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Oh, In-Joon (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Lee, Myung-Hee (Kwangju Christian Hospital) ;
  • Lee, Yong-Bok (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital)
  • 강현아 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소, 전남대학교 병원 임상시험센터) ;
  • 조혜영 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소, 전남대학교 병원 임상시험센터) ;
  • 오인준 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소, 전남대학교 병원 임상시험센터) ;
  • 이명희 (광주기독병원) ;
  • 이용복 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소, 전남대학교 병원 임상시험센터)
  • Published : 2005.08.20

Abstract

Famciclovir is an oral prodrug of the antiherpesvirus nucleoside analogue, penciclovir. In human, famciclovir is orally well absorbed and then undergoes extensive first pass metabolism to penciclovir and essentially no parent compound is recovered from plasma or urine. The purpose of the present study was to evaluate the bioequivalence of two famciclovir tablets, $Famvir^{TM}$ tablet 250 mg (Novartis Korea Ltd.) and Famcivir (Hanmi Pharmaceutical Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of famciclovir from the two famciclovir formulations in vitro was tested using KP VIII Apparatus II method with water. Twenty six healthy male subjects, $24.19{\pm}2.08$ years in age and $71.55{\pm}6.89$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After a single tablet containing 250 mg as famciclovir was orally administered, blood samples were taken at predetermined time intervals and the concentrations of penciclovir in serum were determined using HPLC with UV detector. The dissolution profiles of two formulations were similar at water. In addition, the pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Famvir^{TM}$ tablet 250 mg, were -2.93, -8.02 and 10.47% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log0.8 to log1.25 (e.g., $log0.92{\sim}log1.01$ and $log0.85{\sim}log1.00$ for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Famcivir was bioequivalent to $Famvir^{TM}$ tablet 250 mg.

Keywords

References

  1. S.C. Bioke, M.Pue, P.R. Audet, M.I. Freed, R.E. Ilson and D.K. Jorkasky, Pharmacokinetics of famciclovir in subjects with chronic hepatic disease, J. Clin, Pharmacol., 34, 1199-1207 (1994) https://doi.org/10.1002/j.1552-4604.1994.tb04732.x
  2. K.S. Gill and M.J. Wood, The clinical pharmacokinetics of famciclovir, Clin. Pharmacokinet., 31(1), 1-8 (1996) https://doi.org/10.2165/00003088-199631010-00001
  3. D.K. Kim, N. Lee, D.H. Ryu, Y.W. Kim, J.S. Kim. K. Chang, G.J. Im, W.S. Choi, Y.B. Cho, K.H. Kim, D. Colledge, S. Locarnini, Synthesis and evaluation of 2amino-9-(3-acyloxymethyl-4-alkoxycarbony loxybut-1-yl)purines and 2-amino-9-(3-alkoxycarbonyloxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir, Bioo. Med Chem., 7, 1715-1725 (1999) https://doi.org/10.1016/S0968-0896(99)00086-3
  4. W.S. Choi, G.J. Im, D.K. Kim, T.K. Kim, I. Jung, T.S. Kim, S.J. Lee, N. Lee, Y.W. Kim, J.S. Kim and K Chang, pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir, Drug Metab. Dispos., 29(7), 945-949 (2001)
  5. Y.Y. Lee, S.K. Joung, T.S. Cho, Y.R. Lee, K.R. Lee and H.J. Lee, Bioequivalence of $Famciovir^{TM}$ tablet to $Famvir^{TM}$ tablet (famciclovir 250 mg), The 2004 Preceedings of the Convention of the Pharmaceutical Society of Korea, 433 (2004)
  6. 식품의약품안전청 고시 제 2002-60호, 생물학적동등성시험기준 (2002. 11. 22)
  7. 식품의약품안전청 고시 제 1999-67호, 의약품임상시험관리기준 (2000. 1. 4)
  8. J.R. McMeekin, S.E. Fowles, C.F. Winton and D.M. Pierce, Rapid high-performance liquid chromatographic method for the analysis of the active antiherpes agent, penciclovir and its precursor, BRL 42359, in human plasma and urine following administration of the oral prodrug, famciclovir, Analytical Proceedings, 29, 178-180 (1992)
  9. A. Loregian, R. Gatti, G. Palu and E.F. De Palo, separation methods for acyclovir and related antiviral compounds, J. Chromatography B, 764, 289-311 (2001) https://doi.org/10.1016/S0378-4347(01)00379-6
  10. Statistical Solutions Ltd., Equiv $Test^{\circledR}$ 2.0, UK (2001)